Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

References

• Igarashi A, Hirose E, Kobayashi Y, et al. Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Rev Vaccines. 2021;20(9):1153–1165. Epub 2021 Jul 30. PMID: 34259118.
   PubMed Web of Science ®Google Scholar
• Treskova M, Scholz SM, Kuhlmann A. Cost effectiveness of elderly pneumococcal vaccination in presence of higher-valent pneumococcal conjugate childhood vaccination: systematic literature review with focus on methods and assumptions. Pharmacoeconomics. 2019;37(9):1093–1127. PMID: 31025189.
   PubMed Web of Science ®Google Scholar
• **Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLOS Med. 2020;17(10):e1003326. **This hospital-based test-negative case-control study provides updated estimates of the effectiveness of PPSV23 against vaccine-type pneumococcal pneumonia in adults.
   PubMed Web of Science ®Google Scholar
• Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in england and wales. EClinicalMedicine. 2018;6:42–50.
   PubMedGoogle Scholar
• **WHO Strategic Advisory Group of Experts on Immunization. Pneumococcal vaccination in older adults: report of the SAGE working group on pneumococcal vaccines (Section 9.3). https://www.who.int/immunization/sage/meetings/2020/october/SAGE_eYB_Oct2020final.pdf?ua=1. Accessed 10/28/2021. **This report provides an update and synthesis of published data demonstating the efficacy and effectiveness of pneumococcal polysaccharide and conjugate pneumococcal vaccines against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in older adults.
   Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, et al.; Adult Pneumonia Study Group-Japan (APSG-J). Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–321. Epub 2017 Jan 24. PMID: 28126327.
   PubMed Web of Science ®Google Scholar
• Shimbashi R, Suzuki M, Chang B, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013-2017. Emerg Infect Dis. 2020;26(10):2378–2386. PMID: 32946721; PMCID: PMC7510723.
   PubMed Web of Science ®Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12:e0169368.
   PubMed Web of Science ®Google Scholar
• Berild JD, Winje BA, Vestrheim DF, et al. A systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination on pneumonia and invasive pneumococcal disease in an elderly population. Pathogens. 2020;9:259.
   PubMed Web of Science ®Google Scholar
• Niederman MS, Folaranmi T, Buchwald UK, et al. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev Vaccines. 2021;20(3):243–256. Epub 2021 Feb 20. PMID: 33478306.
   PubMed Web of Science ®Google Scholar
• *Winje BA, Berild JD, Vestrheim DF, et al. Efficacy and effectiveness of pneumococcal vaccination in adults – an update of the literature. [Effekt av pneumokokkvaksine hos eldre] Report 2019. Oslo: Norwegian Institute of Public Health, 2019. *This systematic review is referenced in the WHO SAGE report and synthesizes results from recently published studies to provide updates estimates of pneumococcal vaccine effectiveness against IPD and non-bacteremic pneumococcal pneumonia.
   Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 19;372(12):1114–1125. PMID: 25785969.
   PubMed Web of Science ®Google Scholar
• Meeting of the Strategic Advisory Group of Experts on Immunization. October 2020- conclusions and recommendations. Wkly Epid Rev. 2020; 48(95): 585–608.
   Google Scholar
• Kim JH, Chun BC, Song JY, et al. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study. Vaccine. 2019;37(21):2797–2804. Epub 2019 Apr 17. PMID: 31005428.
   PubMed Web of Science ®Google Scholar
• Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011. Euro Surveill. 2014;19(40):20922. PMID: 25323079.
   PubMedGoogle Scholar
• Su WJ, Chuang PH, Chang LY, et al. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan. BMC Infect Dis. 2021;21(1):45. PMID: 33423657; PMCID: PMC7798272.
   PubMed Web of Science ®Google Scholar
• Nishikawa AM, Sartori AMC, Mainardi GM, et al. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older. Vaccine. 2018;36(19):2510–2522. Epub 2018 Apr 2. PMID: 29618414.
   PubMed Web of Science ®Google Scholar